Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus by Sebastian Eickenberg et al.
RESEARCH ARTICLE Open Access
Mycophenolic acid counteracts B cell proliferation
and plasmablast formation in patients with
systemic lupus erythematosus
Sebastian Eickenberg1,2, Eva Mickholz1,2, Elisabeth Jung1,2, Jerzy-Roch Nofer3, Herrmann Pavenstädt2 and
Annett M Jacobi1,2*
Abstract
Introduction: Clinical trials revealed a high efficacy of mycophenolate mofetil (MMF) in inducing and maintaining
remission in patients with class III-V-lupus nephritis. Also extrarenal manifestations respond to MMF treatment.
However, few attempts have been undertaken to delineate its mechanism of action in systemic lupus
erythematosus (SLE) a disease characterized by enhanced B cell activation.
Methods: Clinical and paraclinical parameters of 107 patients with SLE were recorded consecutively and analyzed
retrospectively. Patients were divided into treatment groups (MMF: n = 39, azathioprine (AZA) n = 30 and controls
without immunosuppressive therapy n = 38). To further delineate the effect of mycophenolic acid (MPA) on naive
and memory B cells in vitro assays were performed.
Results: Although patients taking AZA flared more frequently than patients on MMF or controls, the analysis of
clinical parameters did not reveal significant differences. However, profound differences in paraclinical parameters
were found. B cell frequencies and numbers were significantly higher in patients taking MMF compared to those
on AZA but lower numbers and frequencies of plasmablasts were detected compared to AZA-treated patients or
controls. Notably, MMF treatment was associated with a significantly higher frequency and number of transitional B
cells as well as naive B cells compared to AZA treatment. Differences in T cell subsets were not significant. MPA
abrogated in vitro proliferation of purified B cells completely but had only moderate impact on B cell survival.
Conclusions: The thorough inhibition of B cell activation and plasma cell formation by MMF might explain the
favorable outcomes of previous clinical trials in patients with SLE, since enhanced B cell proliferation is a hallmark
of this disease.
Introduction
Systemic lupus erythematosus (SLE) is characterized by
enhanced B cell proliferation and formation of antibody
secreting cells (ASCs), therefore innovative therapeutic
strategies target those cells. However selective targeting is
a goal not always met. Memory B cells and ASCs have
been shown to be less sensitive to cyclophosphamide [1]
or belimumab [2] than antigen-naïve B cell subsets. In
addition, it has been demonstrated that rituximab [3] and
cyclophosphamide [4] spare long-lived plasma cells. Very
little is known about the impact of other drugs used to
treat or to prevent lupus flares on certain B cell subsets.
Mycophenolate mofetil (MMF) is a drug used as a stan-
dard treatment especially in patients with lupus nephritis.
It is as effective as cyclophosphamide in inducing remis-
sion [5], and in the long run even more effective than
azathioprine (AZA) in maintaining remission of lupus
nephritis [6]. Furthermore, side effects, such as cytopenia
or infertility are less frequently observed in patients treated
with MMF compared to cyclophosphamide [7].
Although the efficacy and safety of MMF have been
thoroughly investigated in patients with severe SLE
[5,8-10], the impact of MMF on B cell aberrations identi-
fied in lupus patients at a time before B-cell depletion
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came into fashion [11,12] has not yet been specifically
addressed.
MMF is a pro-drug of mycophenolic acid (MPA). MPA
reversibly inhibits inosine monophosphate dehydrogenase
(IMPDH). MPA preferentially inhibits type-II-IMPDH
that is upregulated in activated lymphocytes [13-15].
MMF was approved to prevent rejection in kidney allo-
graft recipients in 1995 [16], but it is increasingly used in
patients with autoimmune diseases because of a relatively
high benefit-risk ratio. Since activated lymphocytes depend
on type-II-IMPDH, MPA can theoretically selectively tar-
get these cells mediated by a depletion of the guanosine
pool and deoxyguanosine triphosphate levels, resulting in
cell cycle arrest. This might reduce the probability of side
effects as compared to cytotoxic or other anti-proliferative
drugs such as cyclophosphamide or AZA [17].
However, recent studies have revealed an impact of
MPA on dendritic cells (DCs). Decreased surface expres-
sion of co-stimulatory molecules and a modification of
DC/T cell interaction have been reported [18-20]. Those
might contribute to its positive effects in preventing allo-
graft rejection or nephritis flares. Furthermore, MPA
might show alternate modes of action besides mere gua-
nine nucleotide deprivation. In this context, signal trans-
ducer and activator of transcription 3 (STAT3)
phosphorylation that has been shown to be required for
memory B cell and ASC formation [21,22] seems to be
impaired by MPA in myeloma cells [23]. Also IL-2-
induced STAT5 phosphorylation is altered in MPA-trea-
ted CD3/CD28-activated T cells [24].
Although, there are almost no data available on the effect
of MMF on lupus-specific alterations of DC or lymphocyte
subsets, the effect of MMF on autoimmune mouse strains,
such as MRLlpr/lpr and NZB/W mice, has been studied
thoroughly. An improvement of lupus-related findings is
observed when mice are exposed to MMF [25-29]. MRLlpr
mice are characterized by enhanced B cell proliferation and
extrafollicular differentiation of ASCs [30]. IL-21 has been
shown to promote GC-derived [31] and extrafollicular [32]
B cell proliferation and might therefore contribute to the
generation of self-reactive ASCs in autoimmune mouse
strains such as MRL/lpr mice. Therefore, we chose IL-21
to perform functional assays.
Combining observational data obtained by monitoring
patients with SLE, and results of selected functional assays,
this work develops an idea of how profoundly MPA acts in
patients with SLE. It suggests modes of action that are
advantageous especially in lupus patients.
Materials and methods
Patients
Data were obtained from outpatients attending a lupus
clinic that was started in January 2010 as a joint initiative
of nephrologists and rheumatologists at Münster
University Hospital. All patients underwent standard
laboratory tests allowing an assessment of disease activity
as well as the safety of their current therapeutic regimen.
These tests include all routine diagnostic procedures and
established biomarkers, allowing an assessment of disease
activity, and the patient stratification needed to decide on
the most suitable therapeutic approach. Although no trial
was planned, a characteristic pattern of B cell subsets
became apparent in patients on MMF. A retrospective
analysis of clinical, serological and cellular parameters was
performed to compare patients taking MMF with patients
taking AZA, and patients not taking immunosuppressive
treatment. Ethical approval and informed consent for
monitoring as well as retrospective data analysis were
waived by the local ethics committee. All patients attend-
ing the clinic within its first year were included in this ana-
lysis, provided they had been taking their current
medication for at least six months. Patients treated with
rituximab at any time were excluded, since it causes a sus-
tained alteration of B cell subsets.
Patients were between 18 and 72 years old (mean ± SD,
37.7 ± 12.8), mainly female (85.3%), and fulfilled the
American College of Rheumatology (ACR) criteria for
classification of SLE [33,34]. Regarding immunosuppres-
sive therapy, three groups of patients were distinguished,
namely patients taking AZA (n = 30) or MMF (n = 39), or
not taking any immunosuppressive drugs (n = 38). All
three groups comprised patients suffering flares as well as
patients in remission. Disease activity, individual autoanti-
body profiles, and organ involvement were recorded.
Given the current situation of off-label prescription of
MMF in patients with SLE, patients taking MMF were
slightly younger than the remaining patients (MMF, mean
34.7 ± 11.2 vs. AZA, 38.2 ± 13.3 years, or vs. no immuno-
suppressive therapy, 40.4 ± 13.5 years). Half the patients
taking MMF had been receiving it as induction or mainte-
nance therapy for lupus nephritis since adolescence, initi-
ally prescribed by their pediatricians. The remaining
patients on MMF had AZA-refractory disease or contrain-
dications to receiving cyclophosphamide or AZA. Table 1
gives an overview of the patient characteristics.
Flow cytometric analysis of peripheral blood
lymphocyte subsets
Flow cytometric analysis of peripheral blood mononuc-
lear cells (PBMC) is a procedure performed routinely in
addition to differential blood count in patients under-
going immunosuppressive therapy. From 3 ml of hepari-
nized blood PBMCs were isolated by density gradient
centrifugation using Ficoll-Paque™ Plus from GE
Healthcare (Munich, Germany), were washed in PBS/
0.5% BSA (Sigma-Adlrich, St. Gallen, Switzerland) and
stained immediately with fluorochrome-labeled monoclo-
nal antibodies to a panel of different surface antigens to
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discriminate B and T cell subsets (see Additional file 1).
All samples were processed and analyzed within 6 hours
after collection to ensure viability of all cell subsets. To
exclude dead cells a final concentration of 220 nM 4´,6-
diamidino-2-phenylindole (DAPI) (Invitrogen, Carlsbad,
CA, USA) was used. A FACS Canto-II and FACS Diva
Software (Becton Dickinson, (BD), San Jose, CA, USA)
were used for 12-parameter (8-color) flow cytometric
Table 1 Summary of additional medication, clinical and serologic characteristics of the analyzed lupus patients
AZA MMF No IS
n = 30 % n = 39 % n = 38 %
Medication a
Prednisone 26 87 38 97 14 37
mg/day, median (range) 5.0 (0-50) §§§ 5.0 (0-30)### 0 (0-20)§§§ ###
Hydroxychloroquine 17 57 26 67 29 76
Manifestations a
Nephritis 20 67 35 90 13 34
Proliferative class III, IV of all biopsy results available 12 75 22 76 3 38
CRF grade III+ 5 25 6 17 1 8
Nephritis in remission 9 45 20 57 7 58
Active nephritis 11 55 15 43 6 46
New nephritis 1 5 0 0 6 46
Arthritis 3 10 2 5 9 24
Serositis 1 3 0 0 4 11
Myositis 2 7 1 3 0 0
CNS 1 3 0 0 1 3
Vasculitis 1 3 1 3 1 3
Flaresa 14 47 9 23 12 32
Lupus nephritis flare 10 71 4 44 6 50
CNS flare 0 0 0 0 1 3
Arthritis flare 0 0 2 22 5 42
Serositis flare 2 14 0 0 3 8
Myositis flare 1 7 1 11 0 0
Vasculitis flare 0 0 1 11 0 0
Ref. thrombocytopenia 0 0 1 11 0 0
ILD flare 1 7 0 0 0 0
Autoantibodies a
Anti-dsDNA 27 90 36 92 28 74
C median, U/ml (range) 39 (0-1,250) 29 (0-1,065) 32 (0-1,496)
Anti-Ro 17 57 16 41 24 65
Anti-La 8 27 6 15 10 27
Anti-U1RNP 11 37 14 36 20 54
Anti-SM 6 20 6 15 8 22
APLA/LA 10 33 14 38b 9 28b
Consumption of complement factors a 15 50 16 41 15 39
SLEDAI
Median (range) 6 (0-18) 4 (0-14) 4 (0-24)
Results are presented as number and percent of patients unless otherwise stated. aResulting in an intensification of the immunosuppressive therapy (> 50mg
prednisone-equivalent added, or switch of the therapy regimen to a more potent regimen, such as cyclophosphamide). AZA, azathioprine; MMF, mycophenolate
mophetil; IS, immunosuppression; CRF, chronic renal failure; CNS, central nervous system; ILD, interstitial lung disease; APLA, anti-phospholipid antibodies; LA,
lupus anticoagulant; SLEDAI, SLE disease activity index. bData incomplete (antibody status known in 37 and 32 patients respectively). Statistically significant
differences detected between the dose of prednisone-equivalent, Dunn’s Multiple Comparison test: #P < 0.05, ##P < 0.01, ###P < 0.001 statistically significant
differences between patients taking MMF compared to patients without immunosuppressive therapy (no IS). §P < 0.05, §§P < 0.01, §§§P < 0.001 for statistically
significant differences between patients taking AZA compared to patients without immunosuppressive therapy.
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analysis. One million events were recorded for B cell and
500,000 events for T cell analysis. Results were analyzed
using FlowJo (Treestar, Ashland, OR, USA).
Lymphocyte counts were recorded and absolute num-
bers were calculated using the frequencies of T and B
cells based on the lymphocyte gate and the lymphocyte
count. Differential blood counts and all other lab values
including autoantibody titers were determined in the
central laboratory using accredited diagnostic proce-
dures [35].
Isolation of B cell subsets for functional analysis
Naïve and memory B cells from blood donors (leukocyte
filters) were isolated in a multistep procedure. The use of
leukocyte filters from healthy blood donors for in vitro
assays was approved by the local ethics committee. First
the filter content was incubated with RosetteSep B Cell
Enrichment Cocktail (STEMCELL Technologies SARL,
Grenoble, France) according to the manufacturer’s’ instruc-
tions, and density gradient centrifugation was performed.
Isolated B cells were then labeled with anti-CD27-magnetic
beads (Miltenyi Biotec, Bergisch Gladbach, Germany) and
CD27+ memory B cells were positively selected using a
magnetic column and the Miltenyi Biotec protocol. Subse-
quently the remaining B cells were labeled with biotin-
labeled anti-IgD antibody (IA6-2, BD, Bioscience, Franklin
Lakes, NJ, USA). After washing cells twice with PBS/0.5%
BSA, spreptavidin-labeled magnetic beads (Miltenyi Biotec)
were used for positive selection of CD27-IgD+ naïve B cells
on a second column.
Flow cytometric analysis after magnetic activated cell
sorting (MACS) confirmed that CD3+ T cells were
depleted completely from the CD27+ subset.
Proliferation assay
Naïve and memory B cells were obtained as described
above and subsequently stained with carboxyfluorescein-
succinimidyl-ester (CFSE, Invitrogen) according to the
manufacturers’ instructions. CFSE-labeled cells were then
incubated at a concentration of 105/ml in RPMI 1640
(GIBCO, Invitrogen) supplemented with 10% v/v FCS,
penicillin (100 U/ml) and streptomycin (100 mg/ml) (all
Invitrogen) on a 96-well round-bottom plate (Greiner Bio-
One, Kremsmuenster, Austria) with CpG oligodeoxynu-
cleotide 2006, sequence: 5’-TsCsg sTsCsg sTsTsT sTsgsT
sCsgsT sTsTsT sgsTsC sgsTsT-3’ 2.5 µg/ml (TIB MolBiol,
Berlin, Germany) or 0.5 µg/ml of a monoclonal anti-CD40
antibody (MAB89 (Beckmann Coulter, Eurocenter S.A.,
Nyon, Switzerland) and 50 ng/ml of IL-21 (GIBCO, Invi-
trogen) with or without 5 µM of MPA (Sigma-Aldrich).
Four days later, cells were harvested, washed with PBS,
and stained with monoclonal antibodies (see Additional
file 1) in a 96-well v-bottom plate (Brand, Wertheim, Ger-
many). Proliferation assays were performed in doublets
using peripheral B cell subsets from four healthy blood
donors. Flow cytometric analysis and data processing were
performed as described.
Determination of STAT3 phosphorylation by phospho-
flow cytometry
PBMC were isolated by density gradient centrifugation
and incubated with 5 µM MPA, or without MPA, for
24 hours in RPMI1640 supplemented with 10%v/v FCS,
penicillin (100 U/ml) and streptomycin (100 mg/ml). Sub-
sequently cells were stimulated with IL-21 (50 ng/ml) for
15 minutes at 37°C and fixed in 1.5% formaldehyde
(ROCKLAND Gilbertsville, PA, USA) for 10 minutes at
room temperature. Afterwards PBMC were washed in
PBS/0.5% BSA and stained with fluorescence-labeled
monoclonal antibodies to a panel of different surface anti-
gens to allow the discrimination of B and T cell subsets
(see Additional file 1). After another washing step, cells
were incubated with methanol (ice-cooled, 100%, Riedel-
de-Haen AG, Seelze, Germany) for 10 minutes at 4°C fol-
lowed by two more wash steps. Next intracellular labeling
of pSTAT3 was performed incubating cells with a mono-
clonal antibody (see Additional file 1) for 30 minutes at
4°C. All samples were acquired immediately after two
more wash steps using a FACS Canto-II equipped with
FACS Diva Software (BD) and data were subsequently
analyzed using FlowJo software (Treestar). One million
events were recorded.
Statistical analysis
Frequencies of lymphocyte subsets analyzed ex vivo or in
vitro were calculated using FlowJo software (TreeStar).
Differences in frequencies or numbers of certain cell sub-
sets were determined using the Kruskal-Wallis test and
Dunn’s multiple comparison test, since the majority of
data were not normally distributed. Except for age (pre-
sented as mean ± SD), median values with the range are
shown. The Chi-square test was used to determine if
organ involvement, co-medications or disease flares were
significantly over-, or under-represented in any of the
patient cohorts. The Wilcoxon matched-pairs signed rank
test was performed to compare in vitro cell survival with
and without MPA. P-values < 0.05 were considered statis-
tically significant. Data were analyzed using GraphPad
Prism5 (GraphPad, San Diego, CA, USA).
Results
Clinical aspects
Although AZA- and MMF-treated patients had not been
randomized for important parameters such as disease
activity, prednisone-equivalent dose, disease manifesta-
tions or autoantibody profile, there were no significant
differences in the occurrence of any parameter analyzed
as shown in Table 1.
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Disease flares requiring intensification of the current
treatment regimen by increasing the prednisone-equivalent
dose to > 50 mg/day and/or the dose, or type of immuno-
suppressant, were observed more often in patients taking
AZA (47%) compared to MMF-treated patients (23%).
Organ involvement observed during flares is shown in
Table 1.
Effect of AZA and MMF on peripheral blood lymphocytes
Differential blood counts and flow cytometric data were
analyzed to estimate and compare the effect of AZA and
MMF on cellular parameters. A summary of cell counts is
shown in Table 2. Although patients without immunosup-
pressive treatment had higher T cell numbers than
patients treated with MMF or AZA, no significant differ-
ences were observed. T cell subset analysis did not reveal
significant differences between AZA- and MMF-treated
patients and patients without immunosuppressive therapy.
However, when B cell subsets were compared, a couple of
significant differences were identified. Performance
and results of the B cell subset analysis are shown in
Figures 1, 2, 3.
Although patients on AZA had significantly lower B cell
counts compared to untreated patients or patients taking
MMF (P = 0.0001) (Table 2), CD27highCD38high ASCs
were found at a significantly higher frequency and similar
number in the peripheral blood of these patients com-
pared to patients without immunosuppressive therapy
(data not shown). Importantly, patients taking MMF had
significantly lower frequencies and numbers of ASCs in
the peripheral blood compared to AZA-treated patients,
or patients without immunosuppressive therapy (P <
0.0001 respectively) (data not shown).
In order to analyze if the impact of MMF on the ASC
subset is restricted to recently produced HLA-DRhigh
plasmablasts that usually represent the vast majority of the
CD27highCD38high ASC subset in patients with flaring
lupus, peripheral HLA-DRlow ASC and HLA-DRhigh ASC
were determined and compared (Figure 2). Although the
absolute number of HLA-DRlow ASC was significantly
lower in patients on MMF (P = 0.017, Figure 2B), this
deviation was moderate compared to the marked differ-
ence of HLA-DRhigh ASC counts or frequencies observed
between patient groups (P < 0.0001, Figure 2A). Therefore,
MMF treatment was primarily associated with decreased
frequencies and numbers of HLA-DRhigh ASC in the per-
ipheral blood of lupus patients.
Frequencies and numbers of CD27-IgD+CD38++ transi-
tional B cells were significantly lower in patients taking
AZA compared to MMF-treated patients, or patients
without immunosuppressive therapy (P < 0.0001, Figure
3A). In addition, frequencies and numbers of CD27-IgD
+CD38+ mature naïve B cells were significantly lower in
patients taking AZA compared to MMF-treated patients,
or patients without immunosuppressive therapy (P =
0.0001 and P < 0.0001, respectively, Figure 3B).
In contrast, memory B cell analyses revealed no differ-
ence, or less pronounced differences, between patient
groups (Figures 3C and 3D). Median frequencies of
CD27-IgD- B cells (heterogeneous subset also containing
memory B cells [36]) were comparably high in patients
on MMF (16.2%, range 5.7 to 41.7%), AZA (17.7%, 7.7
to 36.1%) and patients not on immunosuppressive drugs
(17.0%, 4.0 to 33.0%) (data not shown). Also median fre-
quencies of CD27+IgD+ pre-switched memory B cells
did not differ (Figure 3C). The median frequencies of
CD27+IgD- post-switched memory B cells were compar-
ably high in patients on MMF and patients not on
immunosuppressive drugs, whereas AZA-treated
patients had significantly higher frequencies of post-
Table 2 Summary of all cell counts recorded
AZA MMF No IS
Hemoglobin, mmol/l 7.9 (5.5-10.4) 8.2 (5.4-10.7) 8.2 (4.5-10.7)
Platelets/µl 238 (48-459) 252 (136-404) 223 (96-379)
Leukocytes 4855 (2,060-10,160) 5970 (2,640-15,550) 5225 (2,080-9,050)
Lymphocytes/µl 987 (200-3,790) 1080 (360-3,010) 1330 (300-2,910)
B cells % 4.5 (0.6-31.3)* §§§ 9.4 (0.6-40.1)* 11.8 (3.6-28.9)§§§
B cells/µl 44(3-662)** §§§ 113(4-462)** 119 (40-460)§§§
T % of L 76 (28-93)* 63 (24-85)* 64 (42,2-84,5)
T/µl 584 (180-3,286) 640 (89-2,468) 807 (162-2,104)
CD4+ % 73 (39-82) 71 (41-92) 69 (33-92)
CD4+/µl 430 (85-1,709) 466 (61-2,021) 518 (106-1,514)
CD8+ % 19 (7-46) 22 (3-48) 22 (2-60)
CD8+/µl 127 (25-1,410) 144 (12-696) 207 (19-604)
CD4-/CD8- % 6 (2-18) 6 (2-11) 5 (2-20)
CD4-/CD8- /µl 41 (8-136) 41 (2-139) 46 (4-137)
Results are presented as median (range). Statistically significant differences detected between cell counts of patients taking azathioprine (AZA) and
mycophenolate mofetil (MMF) (*P < 0.05, **P < 0.01, ***P < 0.001) and AZA compared to patients not taking immunosuppressive therapy §P < 0.05, §§P < 0.01,
§§§P < 0.001 (Dunn’s multiple comparison test).
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switched memory B cells (P = 0.0003). This comparative
increase was caused by a lack of antigen-naïve B cells
observed in AZA-treated patients. However, absolute
numbers of post-switched memory B cells were compar-
ably high in all patients (Figure 3D).
Effect of MMF on IgG levels
Consistent with the results of B cell subset analysis and
dsDNA antibody levels, patients taking MMF had signifi-
cantly lower IgG levels compared to patients taking AZA,
or patients not on immunosuppressive drugs (P = 0.0005,
Figure 1 Gating strategy. After excluding doublets, CD3, CD14 and CD16-positive cells, CD19+ cells were gated. *Antibody secreting cells
(CD27highCD38high plasmablasts and plasma cells) were subtracted from CD27+IgD- B cells to calculate post-switched memory B cell frequencies.
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Figure 2 Frequencies and absolute numbers of ASC subsets und IgG serum levels. (A) Frequencies and numbers of HLADRhigh antibody-
secreting cells (ASC) were significantly lower in systemic lupus erythematosus (SLE) patients taking mycophenolate mofetil (MMF) compared to
patients on azathioprine (AZA) and patients without immunosuppressive medication (no IS). (B) The absolute number of HLADRlow ASC was
significantly lower in patients on MMF compared to patients without immunosuppressive therapy, whereas the frequency was not. (C) IgG
serum levels (in mg/dl) were also significantly lower in patients taking MMF compared to patients on AZA or without IS. Lower limit of normal
range is marked. Median values are shown: statistically significant differences were detected comparing patients on AZA and MMF (*P < 0.05,
**P < 0.01, ***P < 0.001) or patients on AZA (§P < 0.5, §§P < 0.01, §§§P < 0.001) or patients on MMF (#P < 0.05, ##P < 0.01, ###P < 0.001) to
patients without immunosuppressive therapy (Dunn’s multiple comparison test).
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Figure 3 Frequencies and absolute numbers of B cell subsets. Frequencies and numbers of CD27-IgD+CD38++ transitional (A) and CD27-IgD
+CD38+ naïve B cells (B) were significantly lower in patients taking azathioprine (AZA) compared to mycophenolate mofetil (MMF)-treated
patients or patients not taking immunosuppressive therapy (no IS). Absolute numbers of CD27+IgD+ pre-switched memory B cells (C) were
significantly lower in patients taking AZA compared to patients without IS. However, absolute numbers of CD27+IgD- post-switched memory
B cells did not differ significantly (D). Patients taking AZA had the highest, and patients taking MMF the lowest frequency of CD27+IgD- post-
switched memory B cells (D). Median values are shown: statistically significant differences were detected comparing patients on AZA and MMF
(*P < 0.05, **P < 0.01, ***P < 0.001) or patients on AZA (§P < 0.5, §§P < 0.01, §§§P < 0.001) or patients on MMF (#P < 0.05, ##P < 0.01, ###P < 0.001)
to patients without immunosuppressive therapy (Dunn’s multiple comparison test).
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Figure 2C). Notably, no significant difference was found
between the serum IgG levels of patients on AZA and
patients not taking immunosuppressive drugs (Figure 2C).
However the percentage of patients below the normal
range was comparable in AZA- and MMF-treated patients
(both 10.3%).
In vitro B cell proliferation and differentiation of ASCs are
abolished completely by MPA
B cell proliferation assays were performed as described to
investigate if the impact of MMF on B cell activation and
generation of ASCs that we postulated in patients with
lupus, was indirect or direct. The MPA concentration that
was used in all functional assays had been chosen consid-
ering previous work, and the approximate plasma concen-
tration reached by daily intake of 2-3 g MMF [37].
Proliferation assays of purified CD27-IgD+ antigen-naïve
and CD27+ memory B cell subsets from the peripheral
blood of four healthy blood donors were performed. All
individuals showed a comparable pattern of proliferation
and a representative example is shown (Figure 4). In all
assays MPA was able to abolish B cell proliferation and
differentiation of ASCs completely, no matter if it was
caused by TLR-mediated stimulation using CpG, or by
CD40-antibodies in combination with IL-21, suggesting
that the impact of MMF on B-cell activation and prolifera-
tion is not only related to impaired T cell help. In contrast
to calcineurin inhibitors [38], MMF inhibits B cell activa-
tion and differentiation of ASCs directly.
While proliferation and formation of ASCs were abol-
ished completely, the survival of non-stimulated B cells
was only partially impaired by 5µM MPA after 4 days of
culture (Figure 4). Comparing cell survival in cultures
incubated with and without MPA it was reduced to a
median value of 52.4% for antigen-naïve (range 34.9 to
67.8, P = 0.125) and 76.4% for CD27+ memory B cells
(range 51.1 to 82.3, P = 0.125 (data not shown).
MPA does not affect STAT3 phosphorylation in antigen-
naïve or CD27+ memory B cells
To rule out additional effects of MMF on mechanisms
that are important for B cell proliferation and ASC forma-
tion we also analyzed STAT3 phosphorylation. STAT3
signal transduction is required to form memory B cells
and ASCs [21,22]. It is essential for humoral immune
responses. Phosphorylation of STAT3 has been shown to
be impaired in myeloma cells after incubation with MPA
[23]. Therefore, we decided to investigate the impact of
MPA on IL-21-induced STAT3 phosphorylation in anti-
gen-naïve and CD27+ memory B cells from the peripheral
blood of healthy individuals. As shown in Figure 5, a
24-hour pre-incubation with 5 µM MPA did not impact
STAT3 phosphorylation detected after exposure of CD27-
IgD+ antigen-naïve or CD27+ memory B cells to IL-21.
Discussion
Treatment of lupus patients with MMF causes an
improvement of symptoms as well as normalization of
paraclinical aberrations, such as increased peripheral plas-
mablast counts or hypergammaglobulinemia. Its preferen-
tial effect on B cell activation, proliferation and plasma cell
generation is most welcome in patients with SLE and
seems to be associated with high therapeutic efficacy com-
bined with favorable safety. While controlled clinical trials
have recently demonstrated the latter, this study focused
on paraclinical aspects. Combining observational data and
results obtained by performing selected functional assays
it suggests modes of action that are especially advanta-
geous in lupus, a disease characterized by enhanced B cell
activation and proliferation, as well as plasma cell expan-
sion and autoantibody secretion.
While the beneficial effects of MMF have already been
described years ago in autoimmune mouse models
[25-28] and its impact on aberrations of lymphocyte sub-
sets has been analyzed in mice [29], data on the impact
of MMF on lymphocyte subset alterations in patients
with SLE are rare. Although the current study has limita-
tions because of its observational character, and restric-
tions with regard to the material investigated (blood), the
results still provide explanations for the beneficial effects
observed in vivo. In contrast to AZA or cyclophospha-
mide [1] MMF shows a more selective mechanism of
action. It counteracts the enhanced B cell activation that
is often observed in patients with SLE. In contrast to
AZA, rituximab and cyclophosphamide MMF seems to
spare antigen-naïve B cell subsets. This could be advanta-
geous in infections, when pausing MMF might allow
humoral immune responses to occur. We did not observe
an influence of MPA on resting memory B cells. Com-
pared to the effects observed on B cells, the influence of
MMF on T cell subsets seems to be minor in patients
with SLE. However, comparing peripheral blood T cell
counts and subsets has limitations. Endothelial adhesion
of T cells is impaired by MPA [39]. Therefore, T cell
numbers and subsets in the peripheral blood might not
necessarily reflect the situation found in secondary lym-
phoid organs or inflamed tissue; there, T cell-dependent
antibody responses take place and they might be influ-
enced by MPA. Although, the results of the current study
point to a predominant and direct inhibition of B cell
proliferation and formation of plasmablasts by MPA,
they do not preclude additional effects of this drug on T
cells or DCs.
Until recently, the impact of MMF on human B cell sub-
sets has been neglected, because T lymphocytes enjoyed
unshared attention as key players of allograft rejection. A
study published a few years ago addressed the in vitro
effect of MPA on purified total human B cells and
described an inhibition of CD40-induced proliferation
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Figure 4 MPA abolishes B cell proliferation and plasma cell formation. Mycophenolic acid (MPA) completely abolishes CPG- or anti-CD40
+IL21-induced proliferation of CD27-antigen-naïve B cells (A) or CD27+ memory B cells (B). Results of a representative B cell proliferation assay of
a healthy donor are shown. CD27-IgD+ B cells (A) or CD27+ B cells (B) were isolated, labeled with carboxy-fluorescein-succinimidyl ester (CFSE)
and stimulated for 3 to 4 days as indicated. Gated on live cells, plasmablast gates are shown. Dividing-B cells lose CFSE with any cell division.
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[40]. Another study investigated the effect of starting
MMF, on peripheral B and T cell activation markers in 10
patients with SLE [41] and found a decrease of CD38++
CD19+ B cells in most patients.
In agreement with our results it has been shown very
recently that B cell proliferation and differentiation of
plasma cells is inhibited by MPA even at very low
concentrations (0.3µM), not affecting cell survival [42].
In contrast to B cells, terminally differentiated plasma
cells were unresponsive to MPA even at very high con-
centrations, because of low type-II-IMPDH expression
[42]. In line with this lack of impact on long-lived plasma
cells, the HLA-DRlow ASC subset was only modestly
diminished in patients on MMF compared to HLA-DRhigh
Figure 5 Mycophenolic acid (MPA) does not impact on IL-21-induced signal transducer and activator of transcription 3 (STAT3)
phosphorylation in antigen-naïve and CD27+ memory B cells. After pre-incubating peripheral blood mononuclear cells (PBMC) for 24 hours
with or without MPA, cells were exposed to IL-21 for 15 minutes. STAT3-phosphorylation was determined by phospho-flow cytometry. Gating
procedure of CD19+ B cells and CD27+IgD- memory B cells and CD27-IgD+ antigen-naïve B cells (A) and pSTAT3 of CD27+ memory (B) and
CD27-IgD+ antigen-naïve B cells (C) are shown.
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plasmablasts that were markedly lower in patients taking
MMF compared to patients on AZA, or patients without
immunosuppressive therapy. However, long-term use of
MMF might compromise or skew plasma cell memory by
lacking influx of newly generated plasma cells into the
bone marrow. Although data on vaccination are still lim-
ited, humoral immune responses to influenza vaccination
seem to be impaired more markedly by MMF than by
AZA in kidney transplant recipients and patients with SLE
[43,44]. A defect of humoral immune responses that was
associated with infections was also identified in patients
on MMF for prevention of renal allograft rejection [45].
Even if hypergammaglobulinemia is frequently
observed in lupus patients and low IgG levels that are
associated with infectious complications are rare, the
data suggest that close monitoring of IgG levels is rea-
sonable in patients on MMF, especially when combina-
tions of immunosuppressive drugs are required or
significant proteinuria is present. In addition, flow cyto-
metric monitoring of B cell subsets might help to access
MMF efficacy when starting or weaning off treatment,
and to identify non-adherent or unresponsive patients
with type-II-IMPDH polymorphisms [46].
Summarizing previous and current in vitro results,
MPA seems to act directly on antigen-naïve and memory
B cells, probably mediated by guanosine nucleotide depri-
vation. An additional impact on STAT3 phosphorylation
as observed in a myeloma cell line [23] has not been
detected in human B cells. MPA completely abolished
TLR-mediated polyclonal B cell proliferation, as well as
CD40- and IL-21-induced proliferation. Moreover, altera-
tions of DC or T cell subsets in patients on MMF could
further contribute to the positive impact on B cell subsets
observed in these patients, although those were not the
subjects of this study.
Summarizing the observational data, MMF seems to be
able to ameliorate characteristic disturbances of B cell sub-
sets in patients with SLE, such as an increase in plasma-
blasts, or preferential depletion of antigen-naïve B cells,
which is usually a result of AZA or cyclophosphamide
treatment. These results are in line with the sustained clin-
ical benefit and favorable safety profile observed in
patients treated with MMF for induction or maintenance
therapy of lupus nephritis or extrarenal manifestations.
Conclusion
The thorough inhibition of B cell activation and plasma
cell synthesis by MMF might explain the favorable out-
comes of previous clinical trials in patients with SLE, since
enhanced B cell proliferation is a hallmark of this disease.
Considering the data obtained in this study and the results
of previous randomized clinical trials we suggest that
MMF should be used on a regular basis in patients with
SLE, especially if signs of enhanced B cell activation are
detected, and if maintenance therapy is required for
several years, as in children or young adults with organ-
threatening lupus nephritis.
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